Our experience in the Canadian pharma marketplace runs deep, so you can rest easy.
Canadian Payers want the lowest price — without compromising therapeutic effectiveness. Some of the important trends are:
Provinces negotiating on listing agreements.
Pan Canadian Listing negotiations
Private Payers/Retailers adopting mandatory substitution
Generic pricing reform
Pangaea can help. Our expertise in Strategic Insights & Resourcing expertise is here to help.
Strategic/Brand Planning Facilitation
Topics & Trends™
Managing products in your portfolio from launch to loss of exclusivity is an evolving science. Two key challenges are:
The need to take full advantage of product pipeline.
HCP's that influence product selection in channels vary from province to province.
Pangaea has over 20 years of experience assisting Canadian pharma companies sustain growth and profitability by optimizing product lifecycles.
Launch & LOE Critical Paths
Topics & Trends™
Strategic/ Brand Planning Facilitation
The US Sunshine Act has changed the landscape of corporate governance. When corporate policy spills into Canada, it can limit the ability to compete in this marketplace. Emerging trends include:
Global and industry regulatory bodies’ restricting promotional practices
The need to manage interconnected working relationships within your organization to meet the needs of all stakeholders
Pangaea’s experts can evaluate how corporate governance aligns with Canadian regulations and industry standards:
Benchmarking corporate global codes, Rx&D codes & common practices in Canada
Pangaea represents $2bil in Rx and OTC sales with wholesalers and self-distributing retailers in Canada.
© 2015 Pangaea Holdings Inc. / Pangaea Group